TactiSense IDE Trial of TactiCath SE for Paroxysmal Atrial Fibrillation

NACompletedINTERVENTIONAL
Enrollment

156

Participants

Timeline

Start Date

December 11, 2017

Primary Completion Date

August 2, 2018

Study Completion Date

October 30, 2019

Conditions
Paroxysmal Atrial Fibrillation
Interventions
DEVICE

TactiCath SE

Ablation to achieve pulmonary vein isolation.

Trial Locations (21)

3050

Royal Melbourne Hospital - City Campus, Melbourne

5000

Ashford Hospital, Adelaide

10016

New York University Hospital, New York

10029

Mount Sinai Hospital, New York

20010

Washington Hospital Center, Washington D.C.

20132

Ospedale San Raffaele, Milan

20138

Centro Cardiologico Monzino, Milan

29425

Medical University of South Carolina, Charleston

30322

Emory University Hospital, Atlanta

32803

Florida Hospital, Orlando

40503

Central Baptist Hospital, Lexington

44195

The Cleveland Clinic Foundation, Cleveland

55905

Mayo Clinic, Rochester

72211

Arkansas Heart Hospital, Little Rock

78705

Texas Cardiac Arrhythmia, Austin

80120

South Denver Cardiology Associates, P.C., Littleton

92037

Scripps Health, La Jolla

94062

Sequoia Hospital, Redwood City

Unknown

Royal Adelaide Hospital, Adelaide

04289

Herzzentrum Leipzig GmbH, Leipzig

01307

Herzzentrum Dresden GmbH Universitätsklinik, Dresden

Sponsors
All Listed Sponsors
lead

Abbott Medical Devices

INDUSTRY